Top Companies in Cell and Gene Therapy
Nominate a Company
Usually, the qualified subscribers of our magazine nominate companies with whom they have collaborated and experienced exceptional results to be in this list. Did a company you recently worked with give you stellar results and ROI? Did it turn out to be one you would wholeheartedly recommend to peers? Or do you know of such an outstanding company through your network? Please fill in the details below and nominate them to be featured here.
Top Companies in Cell and Gene Therapy
Cell and Gene Therapy News
Advancing the Future of Personalized Gene Therapy and Cancer Treatment
Tuesday, September 01, 2026
Gene therapy and cancer solutions are transforming the landscape of modern healthcare by introducing innovative approaches to manage various forms of cancer. As scientific understanding of genetics and cellular behavior continues to expand, healthcare researchers and biotechnology organizations are developing therapies that target cancer at its biological source rather than relying solely on conventional treatment methods. These advancements are creating new possibilities for personalized medicine, improved treatment outcomes, and more precise therapeutic interventions. Researchers are increasingly exploring genetic-based solutions that address the underlying mechanisms responsi
Cancer Gene Therapy Moves Toward Commercial Reality as Manufacturing Becomes a Competitive Focus
Wednesday, August 12, 2026
Moving a gene therapy from the laboratory into cancer care has never depended on research alone. As more therapies approach commercial use, manufacturers are facing growing pressure to improve production capacity without compromising quality. The discussion is gradually shifting from scientific discovery to the practical question of how these therapies can be produced efficiently enough to reach more patients. Many current cancer gene therapies, including autologous CAR-T treatments, rely on individualized manufacturing. Cells collected from a patient are modified outside the body before being returned for treatment, making every production cycle unique. While that personalized
Access Becomes the Next Challenge as Gene Therapies Move Deeper Into Cancer Care
Wednesday, August 12, 2026
For many cancer specialists, the conversation around gene therapy is shifting from scientific feasibility to patient access. More therapies are moving through development and gaining regulatory support, yet receiving treatment still depends on factors that extend well beyond clinical eligibility. Manufacturing timelines, referral pathways and reimbursement policies are becoming just as influential as the therapies themselves. CAR-T cell therapy illustrates that shift. The treatment has changed outcomes for certain blood cancers by genetically modifying a patient's own immune cells to recognize and attack cancer. Even as the technology matures, delivering it to patients remai
Gene Therapy Developers Face Growing Pressure to Scale Beyond Clinical Success
Wednesday, August 12, 2026
Gene therapy has generated growing optimism in cancer treatment over the past several years. Clinical advances continue to push the field forward, yet the conversation is no longer centered only on scientific progress. Developers are increasingly expected to show that promising therapies can move from research into routine clinical use without running into manufacturing bottlenecks, lengthy reviews or delivery constraints. That shift is changing how pharmaceutical companies, healthcare providers and investors assess oncology programs. Interest in gene therapy stems from its ability to address disease at the genetic level rather than relying solely on conventional treatment metho
Cell Therapy Developers Put Manufacturing Strategy Earlier in the Pipeline
Thursday, August 06, 2026
Cell therapy product development is becoming more manufacturing-led as companies recognize that clinical promise can weaken if process design is not addressed early. Developers are moving beyond a research-first mindset and placing greater attention on scalability, product consistency, release testing and manufacturing evidence before late-stage trials. The market context supports this shift. The global cell therapy manufacturing market is estimated at USD 6.51 billion in 2026 and is projected to reach USD 17.65 billion by 2033, according to Coherent Market Insights. Growth is being shaped by demand across autologous and allogeneic therapies, along with development activity in o
Regulatory Flexibility Changes the CMC Conversation for Cell Therapies
Wednesday, August 05, 2026
Cell therapy product development is entering a more nuanced regulatory phase as agencies acknowledge the difficulty of applying conventional development expectations to living products. For sponsors, the message is not that standards are lower. Evidence must be planned carefully enough to support flexibility where scientific and manufacturing realities justify it. FDA’s 2026 guidance activity reflects this direction. The agency’s cellular and gene therapy guidance page lists several recent documents, including final guidance on CMC flexibilities for BLA development and draft guidance on leveraging prior knowledge in human gene therapy products incorporating genome ed
